Lipid metabolism disorders in the patiens with chronic renal disease and the possibilities of hypolipidemic therapy

Abstract

Cardiovascular risk in patiens with chronic kidney disease definitely increases with the decline of glomerular filtration. Progression of both renal failure and cardiovascular morbidity and mortality associate with hyperlipidemia and dyslipidémia, characterized by hypertriglyceridemia and decrease of HDL (high-density lipoprotein) cholesterolemia.

Hyperlipidemia and dyslipidemií is treatable by hypolipidemik therapy, including hydroxymethylglutaryl-CoA reduktase inhibitors (statins) and derivatives of fibric acid (fibrates), diet and in some extreme situations by other therapies, such as bariatric surgery.

Keywords

• dyslipidemia
• renal insufficiency
• diabetes mellitus
• coronary heart disease
• atherosclerosis
• metabolic syndrome.